证券日报网讯 12月24日，优宁维在互动平台回答投资者提问时表示，公司主要通过海外电商平台、参 加海外展会等方式对公司自有品牌产品进行海外推广。 （文章来源：证券日报） ...

Core Viewpoint - The company, Youningwei, primarily serves domestic higher education institutions, research institutes, hospitals, and biopharmaceutical companies by providing life science reagents, equipment, consumables, and comprehensive technical services, indicating a broad application of its products across various research fields in life sciences [2] Group 1 - The company focuses on the research sector, targeting higher education institutions and research institutes [2] - The product offerings include life science reagents, equipment, consumables, and technical services [2] - The company's products theoretically have applications in all research areas within life sciences [2]

Core Viewpoint - The company emphasizes the importance of information technology in enhancing its business operations as a one-stop supplier in the life sciences sector [2] Group 1: Business Strategy - The company is continuously upgrading its online marketplace to support its one-stop service model [2] - New systems such as UCRM, CRM, laboratory management systems, OA, and OMS have been launched to improve business and management efficiency [2] - The company is leveraging big data technologies to refine customer profiles based on accumulated customer data, enabling more precise product and service offerings [2] Group 2: Future Outlook - The company will continue to monitor advancements in information technology to further enhance its one-stop service capabilities [2]

Group 1 - The core viewpoint of the news is that You Ning Wei's stock performance and financial metrics indicate a challenging period, with a decline in revenue and net profit, while financing activities show a high level of engagement from investors [1][2][3] Group 2 - As of December 23, You Ning Wei's stock price decreased by 0.17%, with a trading volume of 12.67 million yuan. The financing buy-in amount was 1.24 million yuan, while the net financing buy-in was 399,400 yuan [1] - The total financing and securities lending balance for You Ning Wei reached 63.08 million yuan, accounting for 2.44% of the circulating market value, indicating a high level compared to the past year [1] - The company reported a revenue of 776 million yuan for the first nine months of 2025, a year-on-year decrease of 6.24%, and a net profit attributable to shareholders of -15.08 million yuan, a significant decline of 207.11% [2] - The company has distributed a total of 182 million yuan in dividends since its A-share listing, with 138 million yuan distributed in the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 13.19% to 9,893, while the average circulating shares per person increased by 15.19% to 5,753 shares [2][3]

Group 1 - The company primarily targets domestic higher education institutions, research institutes, hospitals, and biopharmaceutical enterprises in the research sector [2] - It offers a range of products and services including life science reagents, equipment, consumables, and comprehensive technical services [2]

证券日报网讯12月19日，优宁维（301166）在互动平台回答投资者提问时表示，目前公司海外业务占比 较少，主要通过线上网络宣传，新设海外子公司等开拓海外市场。公司后续会根据自主品牌产品研发的 情况，适时加快推进自主品牌产品的出海步伐。 ...

注 1：公司与交通银行股份有限公司、上海浦东发展银行股份有限公司、兴业银行股份有限公司不存 证券代码：301166 证券简称：优宁维 公告编号：2025-094 上海优宁维生物科技股份有限公司 关于使用闲置募集资金及自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"或"优宁维"）于 2025 年 2 月 17 日召开第四届董事会第三次会议和第四届监事会第三次会议，2025 年 3 月 7 日召开 2025 年第二次临时股东大会，审议通过了《关于使用闲置募集资 金及自有资金进行现金管理的议案》，同意公司及并表范围内的子孙公司在不影 响募集资金投资项目建设、不影响公司正常生产经营及确保资金安全的情况下， 使用不超过人民币 30,000 万元（含本数）的闲置募集资金及不超过人民币 150,000 万元（含本数）的自有资金进行现金管理，使用期限自 2025 年 3 月 9 日起 12 个月内有效。公司独立董事和保荐机构均发表了同意意见。具体内容详见公司分 别于 2025 年 2月 19 日和 ...

证券日报网讯 12月18日，优宁维（301166）在互动平台回答投资者提问时表示，公司将围绕一站式平 台极致战略和抗体极致战略，通过抗体上下游应用领域寻找相关标的企业，以实现与现有业务的协同发 展。同时通过开展股份回购计划，加强投资者沟通等方式维护公司股价平稳波动。后续公司将会继续运 用好股份回购、股权激励等工具，努力提升公司经营质量和业绩。 ...

（文章来源：证券日报） 证券日报网讯 12月18日，优宁维在互动平台回答投资者提问时表示，公司围绕一站式平台极致战略和 抗体极致战略，致力于通过围绕抗体上下游应用领域寻找相关标的企业，以实现与现有业务的协同发 展，如有需要披露的实质性进展或达到披露标准的交易，将及时发布公告。2024年至今，公司已推出两 期股份回购计划，首期已实施完毕，第二期回购计划正在实施中，最新的回购情况投资者可关注公司未 来发布的回购进展公告。 ...

Core Viewpoint - The company has made progress in its fundraising projects, with some completed and others still under construction, while focusing on expanding its proprietary brand business under the "extreme antibody" strategy [1] Group 1: Fundraising Projects - Some fundraising projects have been completed, while others are still in the construction phase [1] - Investors can track the progress of these projects through the company's past and future annual and semi-annual reports [1] Group 2: Proprietary Brand Business - The company aims for over 20% growth in its proprietary brand business by the first half of 2025, with an increasing revenue share from these products [1] - The company has enriched its proprietary product offerings, with over 4,200 SPUs developed at the Hangzhou antibody research center and over 1,800 SPUs at the Nanjing protein research center [1] - Future efforts will focus on maintaining stability in third-party brand business while expanding the market for proprietary brands to improve revenue structure and enhance sustainable development capabilities [1]